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Background: Benzodiazepines are commonly prescribed drugs with approximately 10% of adults having used 
them in the past year. These drugs are clearly addictive, yet many patients are prescribed these for years, with long-
term side effects. The present study aimed to investigate whether patients on repeat diazepam prescription had 
their prescription reviewed to reduce and to stop the repeat prescription wherever appropriate, and whether these 
changes were sustained at 24 months.
Methods: The present study used a minimal intervention strategy to reduce diazepam use in a semi-rural general 
practice. Patients with a current prescription for diazepam were invited to visit their general practitioner for a re-
view. Dose reduction grids were formulated for each individual to facilitate a downward titration by 1 mg each wk/
mo. Patients with psychiatric co-morbidity were also included. Interrupted time series methods were applied to the 
monthly data. The outcomes were evaluated at 12 and 24 months.
Results: Ninety-two patients had diazepam on repeat prescription with 87 (94.6%) attending the review appoint-
ment. Twenty-seven patients (29.3%) were under psychiatric review and were supported by the psychiatrist with a 
downward titration regime. At 24 months, 63 patients (81.8% of the 77 still at the practice) had stopped or were in 
the process of stopping regular use of diazepam. A statistically significant reduction in total monthly diazepam pre-
scription was observed (from 2.2 to 0.7 defined daily dose/1,000 patients/d).
Conclusion: This minimal intervention strategy, in collaboration between primary and secondary care, produced a 
durable reduction in overall diazepam prescription at the general practice.
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INTRODUCTION
Benzodiazepines, and particularly diazepam, are commonly pre-
scribed drugs. A recent study has found that almost 10% of the adults 
had taken a benzodiazepine in the past year.1) Benzodiazepines are 
used for the treatment of epilepsy, severe muscle spasm, and as pre-
medicants. However, majority of the prescriptions are for their hyp-
notic and anxiolytic effects. They may also be used as adjuncts in the 
treatment of depression and schizophrenia,1) albeit with scarce evi-
dence.2,3)
 Although useful in the management of generalized anxiety disorder 
(GAD),4,5) perhaps less so in comparison to alternatives when used as 
hypnotics,6,7) these drugs are clearly addictive. Many patients continue 
to take them for years with unknown benefits and likely harms.8)
 NICE (The National Institute for Health and Care Excellence) rec-
ommends the use of benzodiazepines as a short-term measure during 
crisis in GAD, and not routinely for longer than a month.2) Repeat pre-
scriptions should be avoided in patients with major personality disor-
ders or a history of substance misuse. In the latter group, benzodiaze-
pines are often misused alongside other substances,9,10) and are com-
monly implicated in drug related deaths.11)
 Long-term side effects of chronic benzodiazepine use are well docu-
mented. These include increased risk of falls and associated sequel-
ae,12) anterograde amnesia,13) and adverse effects on driving perfor-
mance.14) Withdrawal symptoms can occur after 4–6 weeks, and at 
least a third of long-term users experience problems on dosage reduc-
tion or withdrawal.15)
 The decision to prescribe benzodiazepines is complex and multifac-
torial with particular individual variation.16) Unfortunately, given the 
reduced continuity of care within general practice, unmonitored and 
repeat benzodiazepine prescriptions are common. Long-term side ef-
fects are of particular concern among older adults.12,13)
 In the United Kingdom, the majority of prescriptions in general 
practice are written by medical doctors, with some practices employ-
ing non-medical prescribers such as pharmacists and nurses, who 
have undergone additional postgraduate training. Diazepam, like 
most benzodiazepines and non-benzodiazepine hypnotics, is listed as 
a controlled drug under Misuse of Drugs Regulations 2001 (UK) under 
schedule 4, part 1. It can be prescribed by medical doctors and speci-
fied non-medical prescribers including nurses and pharmacists.
 Linkwood Medical is a semi-rural general practice located in Elgin, 
United Kingdom with a practice population of 11,400. It is an estab-
lished training practice for junior doctors and general practitioner (GP) 
trainees. It has seen a 60% increase in the number of diazepam pre-
scriptions given to patients over the past 4 years after correction for 
practice population numbers. The defined daily dose (DDD) per 1,000 
patients on the practice list per day increased from 1.60 to 2.52 during 
this period. This rise is associated with a wide variation in prescribing 
habits between individual GPs, and has prompted further investiga-
tion.
 Minimal intervention strategies have been demonstrated to increase 
the odds of a patient stopping their benzodiazepine by threefold.17-20) 
These odds are further doubled by creation of systematic reduction 
strategies.17,19) This evidence was the basis for our methodology.
 We had the following questions before the study. Did the patients on 
repeat diazepam prescription have their prescriptions reviewed? If re-
viewed by their own GP, could diazepam doses for the patients on re-
peat diazepam prescription be titrated down? What were the out-
comes for patients at 12 and 24 months?
METHODS
1. Study Design
Formal planning for the study took place from October 2014, including 
identification of patients, with the full intervention taking place be-
tween January 2015 and January 2017. All the patients with “current” 
repeat prescription of diazepam (receiving it at regular intervals with/
without other long-term therapies) were identified on “Vision” (pri-
mary care IT system with electronic patient record and prescribing). 
The individual files were examined for indication, dose, treatment du-
ration, and review details.
 Patients were sent a specific review appointment letter according to 
the appointment capacity. This letter advised the patients about the 
importance of attending the review appointment to allow appropriate 
diazepam prescribing, to receive support, and to discuss any difficul-
ties with their GP. Tapering regimes were formulated by the pharma-
cist prescriber or the medication technician based on current best 
practice.17,21) Dose reduction grids for each patient facilitated a down-
ward titration of 1 mg each wk/mo depending upon the individual cir-
cumstances.
 The pharmacy team determined the exact quantities and doses of 
tablets for the patient while liaising with the local dispensaries. All the 
prescriptions were dispensed weekly, based on current recommenda-
tions.22)
2. Selection of Study Subjects
No exclusion criteria were applied while selecting the subjects. Prob-
lematic benzodiazepine withdrawal is expected in patients with a his-
tory of substance misuse and in those with a co-morbid severe physi-
cal/psychiatric disorder or personality disorder.15,23) Complex patients 
were titrated down, where appropriate, by their psychiatrist after liais-
ing with their GP, and were included in the results.
3. Measurements and Outcomes
Outcomes for deceased individuals or those who had moved practice 
were noted as a part of an attrition analysis. Evaluation was carried out 
at 12 months and 24 months from the beginning of the study to allow 
assessment of the initial effect of the intervention and relapse-preven-
tion.
 Monthly aggregated data from January 2012 to February 2017 were 
extracted from the PIS (Prescribing Information System) using the 
PRISMS (Prescribing Information System for Scotland) database 
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which allows National Health Service (NHS, UK) staff access to pre-
scription data. DDD per 1,000 patients per day of diazepam was se-
lected as a technical, standardized unit to measure the trend in diaze-
pam prescribing over time. This is an assumed average maintenance 
dose per day for a drug and does not necessarily represent true con-
sumption. Data were also obtained for all benzodiazepines.
4. Statistical Analysis
Pre-intervention characteristics of patients with diazepam on repeat 
prescription within the last 6 months were described using counts and 
percentages. Given the temporal nature of the monthly rates of pre-
scriptions of benzodiazepines, and the potential presence of secular 
trends, interrupted time series methodology was used. Two approach-
es were used to evaluate the change in the rates of prescriptions in 
DDDs per 1,000 patients per day. Both the approaches allowed first or-
der autocorrelation-dependence between successive values. The first 
was an autoregressive integrated moving average (ARIMA) regression 
model, which allowed investigation of seasonal patterns alongside 
other parameters by including pairs of sine and cosine terms. This was 
followed by an interrupted time series analysis (ITSA) with Prais-Win-
sten regression model through ITSA in Stata (statistical software pack-
age).24) This method fits a linear regression line through monthly ob-
servations before an intervention and allows a change of intercept at 
intervention (a step up or down in the estimate). It also allows a 
change of slope after the intervention (an entirely different estimated 
change per month). The method enables multiple intervention times 
to represent a change of intercept and slope at the start of the interven-
tion (October 2014) and further changes in both at the full implemen-
tation (January 2015). It also provides estimates, with confidence inter-
vals, of the various intercepts and slopes but has limitations pertaining 
to inclusion of other structures such as seasonality.
5. Ethical Approval
This study was considered a local service evaluation or a quality im-
provement project following review of the proposal by the NHS Gram-
pian Clinical Effectiveness Team. This team is responsible for the reg-
istration of all audit and service evaluation projects that are driven by 
individual clinicians across NHS Grampian. The project was registered 
with their database (ID: 4058). Therefore, ethical approval was not re-
quired.
RESULTS
1. Pre-intervention
Ninety-two patients had a repeat prescription for diazepam. Sixty-one 
percent were male. Age of the patients ranged from 28 to 83 years. The 
average time on diazepam was 81 months (range, 2 months to 23 
years). Forty-five percent of the patients had been on diazepam for 
more than 5 years. The total daily dose was between 2 mg and 25 mg. 
Fifty-seven (62%) of the repeat prescriptions of diazepam were initially 
prescribed for a psychiatric indication. Fifty-two patients (56.5%) had 
undergone a medication review past 4 months.
 Initially, 27 patients (29.3%) were under psychiatric evaluation. 
Their diazepam dose was reviewed and reduced, if appropriate, by 
their psychiatrist. Eight patients (8.7%) were occasionally using ex-
tremely low doses of diazepam and were given a suitable titration plan. 
Fifty-seven patients (62.0%) were eligible for the standard intervention 
(Table 1).
2. Post-intervention
Initial follow-up took place 12 months after the intervention. Atten-
dance was very high, with 87 patients (94.6%) attending the review ap-
pointment to discuss the intervention. At 12 months, 51 patients 
(55.4%) had successfully titrated down and stopped diazepam (Table 
2). Two patients were continued on a slower titration plan, 11 (12.0%) 
were using diazepam intermittently, and 28 (30.4%) were unable to 
stop using diazepam. Due to a boundary change, seven patients had 
moved GP practice. Eighty patients remained at the practice. Five pa-
tients had died. In total, 28 patients (30.4%) were unable to participate 
in a reducing regime.
Table 1. Patient demographics (percentages omitted for counts less than 10) (N=92)
Pre-intervention 
characteristics
Category No. of patients (%)
Gender Male 56 (60.9)
Female 36 (39.1)
Age (y) 20–39 10 (10.9)
40–49 16 (17.4)
50–59 24 (26.1)
60–69 20 (21.7)
70–79 13 (14.1)
80–89 9
Duration of diazepam <12 mo 14 (15.2)
12–36 mo 19 (20.7)
37–60 mo 18 (19.6)
>60 mo 41 (44.6)
Daily dose of diazepam As required dosing 8
<2.5 mg 22 (23.9)
2.5–5 mg 31 (33.7)
5.5–10 mg 19 (20.7)
>10 mg 12 (13.0)
Indication for diazepam Depression or anxiety 40 (43.5)
Addiction 2
Other psychiatric 15 (16.3)
Musculoskeletal pain 16 (17.4)
Neurological conditions 8
Insomnia 4
Other 7
Last review <4 mo 52 (56.5)
4–12 mo 27 (29.3)
>12 mo 13 (14.1)
Clinician review General practitioner 55 (59.8)
Psychiatrist 27 (29.3)
Non-medical prescriber 10 (10.9)
Psychiatry involvement Yes 35 (38.0)
No 50 (54.3)
Previous 7
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 At 24 months since the beginning of the intervention, 58 patients 
(63.0% of the 92 and 75.3% of the 77 still at the practice) had success-
fully titrated down and stopped diazepam. Nine of these patients had 
been given a one-off acute prescription for a specific purpose. Two pa-
tients continued with a slower titration plan, one under practice care, 
and the other by psychiatry. During 2016, 3 more patients moved prac-
tice. Sixty-three patients (81.8% of the 77 still at the practice) had 
stopped or were in the process of stopping regular use of diazepam. 
Out of 14 patients (18.2% of the 77 patients still at the practice) unable 
to stop regular use of diazepam, three patients were under care for 
learning disabilities and five were under care of psychiatry.
 The ARIMA time series analysis showed no evidence of any season-
al effects and these were removed from the models. The ITSA model 
was applied with two points of change of intercept and slope at 
months 34 (October 2014, at the start of the intervention) and 37 (Jan-
uary 2015, at full implementation). For diazepam, the estimated pre-
scribing rate was 1.7 DDD per 1,000 patients per day per month (pp-
dpm), increasing by 0.015 per month (95% confidence interval [CI] 
(Figure 1A), 0.008 to 0.022), to approximately 2.2 DDD per 1,000 pp-
dpm in October 2014 (month 34). There were two substantial but non-
significant step decreases of around 0.3 DDD per 1,000 ppdpm, at the 
start of the intervention (month 34), and at full implementation 
(month 37). There was a non-significant rate of decline of 0.032 DDD 
per 1,000 ppdpm (95% CI, -0.210 to 0.273) during implementation. 
Following full implementation at month 37 (January 2015), the pre-
scribing rate was 1.5 DDD per 1,000 ppdpm with a statistically signifi-
cant linear rate of decline of 0.032 per month (95% CI, 0.022 to 0.042). 
By the end of the study, the prescribing rate was approximately 0.7 
DDD per 1,000 ppdpm (Figure 1A).
 For benzodiazepines (Figure 1B), the estimated initial prescribing 
rate was 2.6 DDD per 1,000 ppdpm, increasing by 0.010 per month 
(95% CI, 0.002 to 0.017) before the intervention, to approximately 2.8 
DDD per 1,000 ppdpm at month 34. At this point, there was a large, 
non-significant step decrease of 0.390 (95% CI, -0.026 to 0.806) and a 
steep decline by 0.126 DDD per 1,000 ppdpm (95% CI, -0.180 to 0.432). 
Following full implementation at month 37, the prescribing rate was 
around 2.0 DDD per 1,000 ppdpm with a shallower decline of 0.032 
DDD per 1,000 ppdpm (95% CI, 0.021 to 0.043) to a rate of 1.3 DDD per 
1,000 ppdpm by the end of the study. The monthly linear declines in 
diazepam and benzodiazepines prescribing rates were almost identi-
cal after full implementation at month 37.
DISCUSSION
1. Summary
At 24 months, the vast majority of patients who were previously on re-
Table 2. Patient outcomes for intervention (N=92)
Outcome
12 Months (January 2016) 24 Months (January 2017)
Total Moved Deceased Still at practice Total Moved Deceased Still at practice
Stopped completely 51 (55.4) 2 2 47 (51.1) 58 (63.0) 4 2 52 (56.5)
On slower titration plan 2 2 2 2
Intermittent use 11 (12.0) 1 10 (10.9) 11 (12.0) 1 1 9 (9.8)
Unable to stop 28 (30.4) 5 2 21 (22.8) 21 (22.8) 5 2 14 (15.2)
Total 92 (100) 7 5 80 (87.0) 92 (100) 10 (10.8) 5 77 (83.7)
Values are presented as number (%) or number.
Figure 1. Observed and predicted DDD per 1,000 patients per day for diazepam (A) and benzodiazepine (B) with change points in October 2014 and January 2015 (months 
34 and 37). DDD, defined daily dose.
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peat diazepam prescriptions were completely off the medication, with 
a smaller proportion using diazepam on an intermittent and specific 
basis.
2. Strengths and Limitations
The success of this intervention can be attributed to many factors, all 
involving multidisciplinary teamwork including the planning of ap-
pointments, advance preparation of individual diazepam dosing 
charts and prescriptions, documentation of stages in the notes, and 
monitoring of patient attendance. The project depended on shared 
understanding from the GPs and the pharmacy team.
 Individual circumstances were considered before agreeing on 
downward titration plans. We achieved good concordance and pa-
tients were strongly encouraged to stay on plan, rather than reduce the 
dose more rapidly than the recommended regimen. Patients on long-
standing diazepam prescriptions were given a monthly dose reduction 
and those on shorter term or smaller doses, a weekly dose reduction. It 
was considered important that patients were scheduled with their 
usual GP.
 An effective working relationship with the local psychiatrist, for ad-
vice and discussion, was advantageous for more complex patients. 
This included weekly clinics to consult with patients, and a quarterly 
meeting with clinicians at the practice to discuss patients’ progress. 
The psychiatrist established and concurred the plans with their pa-
tients who were able to reduce their diazepam.
 The present study had some limitations. A gold standard follow-up 
investigation could have included repeat urine drug screens on com-
pletion of the titration regime. This would have confirmed that patients 
were not sourcing diazepam from alternative means. This was difficult 
to justify in a group that was using diazepam regularly but was not 
likely to meet diagnostic criteria for benzodiazepine dependence.25)
 Diazepam was the only benzodiazepine examined separately. A 
similar study of other commonly prescribed benzodiazepines could 
have been conducted. However, it would have involved far fewer pa-
tients. Figure 1B demonstrates that there was no compensatory pat-
tern of prescribing alternative benzodiazepines while diazepam pre-
scribing had reduced.
 Ten patients (10.9%) had moved to neighboring GP practices due to 
a newly enforced boundary change. The change in practice policy of 
prescribing diazepam was not a factor for patients moving to other 
practices as confirmed by our attrition analysis.
3. Comparison with Existing Literature
The findings in the present study are consistent with those of previous 
studies on the successful use of minimal intervention strategies in pri-
mary care.17-20) In contrast to similar studies,19,20) our coordination with 
the local psychiatrist allowed the investigation of the intervention on 
patients involved with psychiatry and substance misuse services.
 There has been limited research into relapse prevention following 
such interventions with the exception of two studies. In comparison to 
the study by Voshaar et al.,26) the present study was more proactive by 
ensuring all the patients at the practice had an attempted reduction, 
rather than a patient-led opt-in with comparatively favorable results. 
Vicens et al.27) found that an intense follow-up regime was demon-
strated similar efficacy to a structured intervention with written in-
structions, which supports the decision to use the latter approach in 
our study. Both the studies excluded psychiatric patients.
4. Implications for Research and/or Practice
New patients to this practice, who are on repeat prescriptions of diaze-
pam, are immediately scheduled for an appointment with a GP to re-
view their diazepam prescription. For patients authorized to use diaz-
epam on an as required basis, the medical files are clearly annotated 
with the amount and frequency of the authorized dose. It is practice 
policy for diazepam to be dispensed weekly for all patients. These are 
important long-term safeguards to ensure that a patient’s use of the 
drug does not change without good reason or review. This should be 
considered a gold standard for General Practice in prescribing diaze-
pam and other drugs with a propensity for causing iatrogenic depen-
dence.
 Future challenges remain, with arguably the most complex patients 
continuing to receive long-term diazepam prescriptions, which are 
advised by their secondary care provider (psychiatry, learning disabili-
ties or substance misuse services). In these cases, there is an evidence 
base supporting long-term benzodiazepine use.28) A collaborative dia-
logue between primary and secondary care is imperative for reducing 
the number of patients remaining on diazepam prescriptions when 
not clinically indicated.
 There is growing evidence for encouraging approaches that modify 
GP attitudes towards prescribing benzodiazepines and utilizing non-
pharmacological alternatives.29,30) Maintenance of positive prescribing 
practices and associated attitudes between GP partners has been 
streamlined through practice meetings and a practice protocol for the 
prescribing of diazepam. This information has been added to the 
practice’s induction program and locum pack. This could be imple-
mented in all similar teaching practices.
5. Conclusion
To summarize, this study has been able to produce a statistically sig-
nificant, durable reduction in overall diazepam prescribing by using a 
minimal intervention strategy and maintaining a collaborative, proac-
tive relationship between primary and secondary care providers.
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